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Abstract
Background: Non-adherence to antidepressants generates higher costs for the treatment of depression. Little is known
about the cost-effectiveness of pharmacist’s interventions aimed at improving adherence to antidepressants. The study
aimed to evaluate the cost-effectiveness of a community pharmacist intervention in comparison with usual care in
depressed patients initiating treatment with antidepressants in primary care.
Methods: Patients were recruited by general practitioners and randomized to community pharmacist intervention (87) that
received an educational intervention and usual care (92). Adherence to antidepressants, clinical symptoms, Quality-Adjusted
Life-Years (QALYs), use of healthcare services and productivity losses were measured at baseline, 3 and 6 months.
Results: There were no significant differences between groups in costs or effects. From a societal perspective, the
incremental cost-effectiveness ratio (ICER) for the community pharmacist intervention compared with usual care was
J1,866 for extra adherent patient and J9,872 per extra QALY. In terms of remission of depressive symptoms, the usual care
dominated the community pharmacist intervention. If willingness to pay (WTP) is J30,000 per extra adherent patient,
remission of symptoms or QALYs, the probability of the community pharmacist intervention being cost-effective was 0.71,
0.46 and 0.75, respectively (societal perspective). From a healthcare perspective, the probability of the community
pharmacist intervention being cost-effective in terms of adherence, QALYs and remission was of 0.71, 0.76 and 0.46,
respectively, if WTP is J30,000.
Conclusion: A brief community pharmacist intervention addressed to depressed patients initiating antidepressant
treatment showed a probability of being cost-effective of 0.71 and 0.75 in terms of improvement of adherence and QALYs,
respectively, when compared to usual care. Regular implementation of the community pharmacist intervention is not
recommended.
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Introduction
Major depression is a highly prevalent disorder that generates a
heavy burden both for the society and the public health system [1–
3]. Major depression also imposes a substantial financial burden
on society through increased health care utilization and absentee-
ism from paid work [4].
The cost associated with mental disorders currently accounts for
approximately 3%–4% of gross domestic product in Europe [5].
In Catalonia, a Spanish region with a population of around 7.5
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million inhabitants, the annual cost of major depression in 2006
was 735 million Euros [6]. Productivity loss (indirect costs),
accounted for almost the 79% of total costs.
Almost 70% of patients with a mood disorder are prescribed
psychotropic drugs, mainly antidepressant [7,8]. Non-adherence
to antidepressants is high, as shown by recently published studies
that reported rates of non-adherence of over 75% after 6 months
[9–11]. This low rates of adherence to antidepressants prevent
patients to benefit fully from the effects of the treatment, increasing
the costs and the risk of relapse and recurrence [12–14].
A number of interventions aimed at improving patients’
adherence to antidepressants have been evaluated [15]. Some
efforts have concentrated on pharmacists, in their role of drug
dispensers and specialists on medication showing a positive effect
on adherence to antidepressants [16]. The PRODEFAR study was
focused on a community pharmacist’s intervention in depressed
patients [17]. The pharmacist intervention being evaluated
showed to impact positively on patients’ health-related quality of
life and the impact on the levels of adherence to antidepressants
was almost statistically significant in the per protocol analysis. The
severity of depressive symptoms was not affected by the
intervention [17].
Economic evaluations provide decision-makers with informa-
tion on how to allocate the limited resources available for health
care. However, only one study evaluated the cost-effectiveness of a
pharmacist’s intervention to improve adherence to antidepressants
[18]. The study considered a small sample size both in the main
analysis (N = 88) and in the per protocol analysis (only 26 patients
in the intervention group). Besides, this study did not include
quality adjusted life years (QALY) as a measure of effectiveness
thus limiting comparison with other therapies and therapeutic
areas [19].
The aim of the present study was to evaluate the cost-
effectiveness of a community pharmacist intervention (CPI) in
comparison with usual care (UC) for depressed patient initiating
treatment with antidepressants in primary care. The economic
evaluation was completed from a societal and a healthcare
perspective.
Materials and Methods
Economic evaluation conducted alongside a naturalistic ran-
domized controlled trial with 6 months of follow-up comparing a
CPI with UC for patients prescribed a new antidepressant
treatment by a general practitioner (GP). A detailed description
of the study protocol has been provided elsewhere [17,20]. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1. The study protocol was approved by the Fundacio´ Ethics
Committee. Patients signed an informed consent to participate.
Study population
Participants were recruited in 4 Primary Care Health Centres
(30 GPs) from two cities (Gava` and El Prat) in the metropolitan
area of Barcelona (1 October 2008–31 May 2011). At first, only
the PCHC from Gava` participated in the study but to accelerate
patient inclusion, a population from El Prat was included in
March 2010. Eligible patients were adults aged 18–75 initiating
treatment with antidepressants because of depression. Depression
was assessed using the research version of the Structured Clinical
Interview for DSM-IV (SCID-I) [21,22]. GPs were blind to the
DSM-IV diagnosis and patient inclusion was performed according
to their usual practice.
Randomization
Randomization was done at the patient level using a comput-
erized random-number generator following a permuted block
design. Every GP received a set of 10 sequentially numbered,
opaque, sealed envelopes containing patient assignment. The GP
sequentially stapled one of the envelopes to the patient’s
prescription that was opened by the pharmacist in the community
pharmacy. Pharmacists were asked to be careful not to use
intervention elements in their contacts with the UC group.
Patients were asked to avoid conversations concerning the study
with other participating patients.
Interventions
Patients received the CPI when they went to the pharmacy to
pick up their first prescription of antidepressants (mean time
invested of 14.4 minutes). A shorter version of the intervention was
used as a reminder when patients refilled their prescriptions (mean
time invested of 7.7 minutes). The CPI consisted of an educational
intervention provided by the pharmacist and focused on improv-
ing patients’ knowledge of antidepressant medication, as well as
making patients aware of the importance of compliance to the
medication, to reassure the patient about possible side-effects, and
to stress the importance of carrying out GPs’ advice. Also, in
patients with a sceptical attitude towards antidepressants, the
intervention aimed to reduce stigma. Pharmacists participating in
the study were trained for the intervention.
Patients in the UC group received usual care from their GP and
pharmacist. The intervention in the usual care group consisted of
filling the prescriptions, addressing patients’ questions about
medication and giving basic advice about how to take the
antidepressant. Pharmacists invested a mean of 7.8 minutes per
patient for the first visit and 7.7 minutes for subsequent visits.
Clinical outcomes
Adherence was measured using electronic pharmacy records.
Every time the patient refills his/her medication the system
automatically registers the information in the patient’s clinical
history. This method for assessing adherence provides a good
estimate of adherence and has been recommended both in
research and clinical contexts [23].
Originally, the intention was for pharmacists to manually
register the information on medication dispensed. However, the
electronic system was much more reliable and easy to execute and
was not affected by the mobility of the patients or the loss to
follow-up. The medication possession ratio (MPR) was calculated
as (Number of doses refilled/Number of doses prescribed)*100.
Some patients abandoned the treatment right after commence-
ment and, after some months without treatment, suffered a relapse
and initiated a new treatment. In some cases, the amount of
antidepressant drugs refilled by those patients, if we took into
account the whole 6-months, period was over the 80%.
Consequently, continuity in the acquisition of medication was
also checked. Patients were considered to have a drug gap if there
was a period of 2 or more months without medication. Poor
adherence was defined as having a MPR,80% or having a
medication gap [24].
QALYs and severity of depression were assessed at baseline, and
3 and 6 months of follow-up.
Health-related quality of life was measured using the EuroQol-
5D [25–27] and Spanish tariffs were used to estimate the utility of
health states described by the patients [28]. QALYs were
calculated by multiplying the utility with the amount of time a
patient spent in a particular health state. Linear interpolation was
used for transitions between health states.
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Severity of depression was assessed using the Patient Health
Questionnaire 9-item depression module (PHQ-9) [29,30].
Remission of symptoms was considered as having a reduction in
PHQ-9 scores superior to 50% [31].
Service utilization and cost measures
Cost data were collected from a societal perspective at baseline,
3 and 6 months. Use of health care resources and lost productivity
were assessed with the Client Service Receipt Inventory with a
three months recall period [32]. Information about use of
psychotropic drugs was collected from computerized pharmacy
records. Intervention costs were estimated using the patient study
chart kept by the pharmacist. Pharmacists registered the time
spend with the CPI and UC patients in each visit to the pharmacy.
A secondary analysis was done from a health system perspective
(indirect costs excluded).
Direct healthcare costs comprised visits to publicly and privately
funded primary and secondary care providers, hospitalisation,
tests, and drugs. The Official Bulletin of the Catalan Government
for 2009 was used to estimate the costs of publicly funded services
[33]. For privately funded services, we used the information
provided by the Official College of Physicians of Barcelona [34].
Indirect costs consisted of the costs of absenteeism from paid
work. Costs of work loss were calculated by multiplying the days
on sick leave with the minimum daily wage in Spain according to
the human capital approach [35].
The unit cost of the community pharmacists was calculated
taking into account the pharmacists annum working time as well
as general community pharmacy expenses, pharmacists salaries
and salaries on costs, taxes and pharmacists annum working time.
This information was extracted from a published annual report
based on income tax return declarations from Spanish community
pharmacies in 2009 [36].
In the CPI group extra costs were included to account for the
time spent on the training by the pharmacists. Training costs were
estimated by adding the tariffs of the Official College of
Pharmacists from Barcelona for similar training courses with the
time spent by the pharmacists on the training and taking into
account the 12-month incidence of depression in primary care
Catalan population.
Table 1 shows the unit costs healthcare resources. Time horizon
was less than a year so costs were not discounted.
Statistical methods
The main analyses were done according to the intention to treat
principle (ITT). Sample size calculation was based on the primary
outcome of the study, i.e. adherence to antidepressants. To
observe an improvement of 17 points in the percentage of
medication intake and assuming a one-sided alpha of 0.05 and a
power of 0.8 a total of 162 patients were necessary. We explored
baseline differences between groups with Students t-test, x2-test (or
Fisher exact test), and the non-parametric K-sample test on the
equality-of-median.
Missing data. Fifty-five percent of individuals had at least
one missing clinical or cost variable. We cannot be certain about
the reasons for the missing data, but no major discrepancy was
found between imputed data and complete-case analysis so we are
leaning towards its classification as missing at random. Missing
values were imputed using multiple imputation by chained
equations using the predictive mean matching method. The
imputation model included important sociodemographic and
prognostic variables associated with the outcome variables and
drop-outs (education and presence of depression according to
DSM-IV criteria). Fifty imputed databases were created [37].
Cost-effectiveness calculations. The incremental costs and
effects between groups were modelled by generalized linear
models (GLMs) that were fitted with different distribution families
(gaussian, inverse gaussian, poisson and gamma) and link functions
(identity and log). Akaike and Bayesian information criterion
(AIC/BIC) were used to test the models.
For the costs and the QALYs, the gamma and gaussian
distribution, respectively, with identity link were the best fit. For
adherence to antidepressants and remission of symptoms, a
binomial distribution with logit link was used. Sociodemographic
and baseline clinical variables considered to be relevant were
tested in the models using likelihood ratio tests (p#0.10).
Unadjusted and adjusted analyses are presented.
The overall difference in mean costs and effects between
treatments was calculated using Rubin’s rules [38]. We calculated
the incremental cost-effectiveness ratio (ICER) by dividing the
difference in costs between the treatments by the difference in
effects.
Generation of cost-effectiveness planes and cost-
effectiveness acceptability curves
To estimate the uncertainty surrounding the cost differences
and the ICER, we used bootstrapping with 500 replications in
each imputed dataset. Due to the biased and skewed distribution
of the costs, a bias-corrected and accelerated (BCa) confidence
interval [39] was estimated on each imputed dataset and then
averaged.
Bootstrapped cost effect pairs were then plotted on cost
effectiveness planes [19] and used to estimate cost effectiveness
acceptability curves (CEACs) [40]. Analyses were performed with
STATA 12.0.
Sensitivity analyses
Five sensitivity analyses were conducted to assess the robustness
of the results. Firstly, we did a Per Protocol (PP) analysis in which
patients in who did not attend to the pharmacy or receive the
intervention were excluded. Secondly, we did a complete case
analysis without the 52 patients who were lost to follow-up at 6
months. Thirdly, we conducted an analysis where the intervention
costs were doubled. Fourthly, we carried out an analysis using the
mean salary (52.3J per day) instead of the minimum salary in
Spain. Finally, we did an analysis considering only those patients
that fulfilled DSM-IV criteria for depression.
Results
Figure 1 shows the flow chart of the study. GPs referred 179
patients that met the inclusion criteria, consented to participate
and were randomized to the CPI (n = 87) or UC group (n = 92).
Table 2 shows the baseline characteristics in intervention and
control group. Most participants were women (75%), with mean
age of 46.6 years. 51% of the participants met DSM-IV criteria for
major depression. Statistically significant differences existed in the
proportion of women between the two groups. No other baseline
differences existed between groups. Sixty-four and 87 patients in
the CPI and UC group, respectively, received the intervention as
allocated and were included in the PP analysis. 71% of patients
attended the 6 months follow-up assessment and were included in
the complete-case analysis.
Cost-effectiveness analyses
Table 3 lists unadjusted costs in the control and intervention
groups during 6 months.
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Overall costs tended to be higher in the CPI group than in UC
patients although not statistically significantly so. The largest part
of the cost difference (over 90%) was due to the difference in
indirect costs (productivity loss). The intervention costs were
statistically significantly higher in the CPI group than in the UC
group (Table 3).
Table 4 shows the cost-effectiveness analysis after 6 months
follow-up. No statistically significant differences were observed
between groups in costs or clinical outcomes, neither in the
adjusted or unadjusted analysis (Table 4), although costs were
slightly higher in the CPI group.
Societal perspective. The bootstrapped cost-effectiveness
pairs for the CPI effects on adherence were primarily located in
the northeast (64%) and northwest (26%) quadrant, indicating that
the costs in the CPI group were higher but that adherence did not
differ between groups (Figure 2). The ICER indicated that J1,866
needs to be invested per extra adherent patient (Table 4).
Similar results were found for QALYs (Table 4). The CPI group
showed both higher costs and a small increase in terms of QALYs
compared with UC, resulting in an ICUR of J9,872.
Whereas costs were higher, the CPI group showed a negative
improvement in the remission of depressive symptoms, resulting in
a negative ICER (Table 4) (UC dominated the CPI).
The CEACs showed that the probability of the intervention
being cost-effective was 0.71 if the society is willing to pay J17,000
for one extra adherent patient (Figure 2). In terms of remission of
symptoms and QALY, if we take into account a WTP of J500 per
extra remitted patient or QALY, the probability of the CPI being
cost-effective in comparison with UC was 0.44 and 0.71,
respectively.
If willingness to pay (WTP) is J30,000 per one extra adherent
patient, per extra remission of symptoms or per QALY, the
probability of the CPI being cost-effective was 0.71, 0.46 and 0.75,
respectively.
Health system perspective. Since indirect costs were
responsible for most of the difference in total societal costs
between the groups, when the healthcare perspective was used the
cost difference became smaller. As a result, the cost-effect pairs
were more evenly distributed among the northern and southern
quadrants in the CE plane (Table 4). The ICER was J962 per
extra adherent patient for the CPI compared with UC.
The ICER was also smaller in terms of QALYs (J3,592 per
extra QALY). In terms of remission of symptoms, the UC still
dominated the CPI (J-3,946 per one extra remission).
From a health system perspective, the probability of the
intervention being cost-effective is 0.71 if the WTP is J6,000 for
an extra adherent patient and J100 for an extra QALY. If
WTP is J30,000 per one extra adherent patient or QALY, the
probability of the CPI being cost-effective was 0.71 and 0.76,
respectively.
In terms of remission of symptoms, the maximum probability of
CPI being cost-effective in comparison with UC (i.e. even if WTPis
an infinite amount of money) was 0.46.
Sensitivity analyses
Results of the sensitivity analyses were mainly in concordance
with the main analyses and led to the same conclusions as the main
analyses (Table 4).
In the PP analysis, costs differences were slightly larger than in
the main analysis but effectiveness of the CPI was also larger in
terms of adherence thus reducing the ICER (J1,455) and
increasing the probability of CPI being cost-effective to 0.77 if
WTP is J17,000. On the other hand, no difference in QALYs was
observed in the PP analysis and consequently the ICER increased
(J25,522).
The complete case and the DSM-IV criteria analysis showed
smaller differences in adherence but the difference in costs was also
reduced, not altering the results from the main analyses much.
Table 1. Unit costs for healthcare resources in Euros (year 2009 values).
Type of utilisation Unit costs
Costs in the public health care system General practitioner 36.0
Nurse 14.0
Psychologist 51.6
Psychiatrist 51.6
Other medical specialists 51.6
Hospital emergency visits 142.7
Hospital stay (per day) 277.6
Diagnostic tests Range 3.7–329.0
Pharmacological treatment Depending on type and dose
Social worker 36.0
Costs in the private health care system Psychiatrist 25.3
Psychologist 25.3
Medical specialist 25.3
General practitioner 25.3
Productivity losses Abstenteeism from work (Number or net days) 24.0
Intervention costs Pharmacist (per hour) 68.3
Extra per-patient cost in the community pharmacist
intervention groupa
5
aIn the intervention group an extra 5 J per patient were included to account for the time needed for the training of the pharmacists.
doi:10.1371/journal.pone.0070588.t001
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Results of the sensitivity analyses in which the intervention costs
were doubled or the average salary was used instead of the
minimum salary did not differ from the main analysis.
Discussion
Main findings
The aim of the present study was to assess the cost-effectiveness
after 6 months of a brief CPI compared to UC on the
improvement of adherence, QALYs and clinical symptoms in
primary care patients starting pharmacological treatment for
depression.
The effectiveness analysis showed no statistically significant
differences between groups in either adherence, depressive
symptoms or QALYs. Total costs were higher in the CPI group,
mainly as a consequence of increased costs in productivity losses.
Cost-effectiveness planes and CEACs showed that a brief CPI had
a probability of only 0.71 and 0.75 in terms of improvement of
adherence and QALY, respectively, of being cost-effective when
compared to UC. The CPI was unlikely to be cost-effective in
comparison with UC in terms of remission of symptoms.
Comparison with previous findings
Until now, to the best of our knowledge, only one study has
been published on the cost-effectiveness of a pharmacist interven-
tion for depression [17]. Bosmans et al conducted a randomized
controlled trial in The Netherlands in which a pharmacist
intervention plus a take-home educational videotape were
compared to UC for patients with depression initiating
treatment with antidepressants. Bosmans and colleagues found
no impact of the intervention on the improvement of adherence
or clinical symptoms of depression. In their study, total costs
were slightly higher in the intervention group but the difference
was not statistically significant. As was the case in the present
study, in the study by Bosmans et al indirect costs accounted for
most of the difference in total costs between groups, although
the difference between groups in indirect costs was not
statistically significant.
Bosmans et al found little evidence supporting the cost-
effectiveneness of a brief educative pharmacist intervention into
clinical practice, which is consistent with the results observed in
the present paper.
Schoenbaum and colleagues evaluated the impact of support
medication adherence program that was implemented via the
telephone by trained practice nurses [41]. In this study, the
intervention group generated higher costs but differences were not
statistically significant. No statistically significant differences in
QALYs were observed between the intervention and UC groups
and ICER was J37,422 (adjusted to 2009 Euros). This result is in
line with the results presented in the present paper showing that in
Figure 1. Flow-chart of the study.
doi:10.1371/journal.pone.0070588.g001
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terms of QALYs, low intensity educative interventions imple-
mented by community pharmacists are not cost-effective in
comparison with UC when dealing with depressed patients who
start antidepressant treatment.
Strengths and limitations
Economic evaluations are highly affected by sampling uncer-
tainty. Size calculation was based on the improvement in
adherence to antidepressants and the study could have been
underpowered to detect differences in the cost-effectiveness
analysis. However, to the best of our knowledge, our study has
the largest sample size used to evaluate the cost-effectiveness of a
pharmacist intervention in depressed patients.
Second, patients in the intervention and control group attended
the same community pharmacies and contamination of the control
group could have occurred. This could have been prevented by
Table 2. Socio-demographic and clinical baseline characteristics of the sample.
Usual care
(n = 92)
Pharmacist’s intervention
(n = 87)
Gender; % women (n)* 83.7% (77) 66.7% (58)
Age; mean (95% CI) 46.3 (43.3–49.2) 46.9 (44.0–48.6)
Marital status; % (n) Never married 14.1% (13) 18.4% (16)
Married or living with someone 64.1% (59) 59.8% (52)
Previously married 10.9% (10) 10.3% (9)
Widow 10.9% (10) 11.5% (10)
Education; % (n) No studies 7.6% (7) 5.8% (5)
Primary 22.8% (21) 23.0%(20)
Graduated 23.9% (22) 19.5% (17)
Secondary 26.1% (24) 31.0% (27)
University 19.6% (18) 19.0% (34)
Others – 2.3% (2)
Working status; % (n) Househusband/housewife 13.0% (12) 17.2% (15)
Paid employment 40.2% (37) 29.9% (26)
Paid employment but on sick leave 21.7% (20) 24.1% (21)
Unemployed 17.4% (16) 16.1% (14)
Retired 7.6% (7) 9.2% (8)
Others – 2.3% (2)
NS/NC (Missing) 1.2% (1)
Major depression according to
DSM-IV criteria; % (n)
50.0% (45) 52.3% (45)
Clinical severity according to PHQ-9;
mean (95% CI)a
15.8 (14.6–16.9) 16.1 (14.7–17.4)
Number of co-morbidities; % of cases
over the median (n)
37.0% (34) 40.2% (35)
*p,0.05.
aPHQ-9 scores can range from 0 to 27, with scores of 15 to 19 corresponding to moderately severe symptoms.
doi:10.1371/journal.pone.0070588.t002
Table 3. Multiple imputed and pooled costs after 6 months follow-up in the usual care and interventioun groups and mean
differences between groups (95% CI) (unadjusted analysis).
Type of cost Usual care Intervention Mean differences
Direct costs 409 (303, 515) 412 (322, 502) 3 (2134, 140)
Visits to primary and secondary care 185 (143, 228) 225 (165, 284) 39 (227, 106)
Emergency visits and hospitalisation 113 (49, 176) 86 (39, 134) 226 (2107, 54)
Diagnostic tests 61 (30, 92) 44 (26, 63) 217 (251, 16)
Medication costs 50 (38, 62) 57 (44, 69) 7 (210, 24)
Intervention costs 16 (13, 20) 32 (27, 37) 16 (9, 22)
Indirect costs (sick leave) 342 (110, 573) 647 (351, 943) 306 (295, 706)
Total costs 767 (499, 1035) 1091 (764, 1418) 324 (297, 745)
doi:10.1371/journal.pone.0070588.t003
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performing a cluster randomization at the pharmacy level. To
minimise the impact of this contamination, pharmacists were
asked to be aware of contamination when attending patients in the
UC instead than at the patient level group and patients were asked
not to share information with other patients participating in the
study.
Third, the GPs that participated in the study could have had a
special interest in the topic under study and could have routinely
conducted interventions to improve patients’ adherence to
antidepressants. Although this would have affected both UC and
CPI groups, it could have limited the margin of improvement of
the pharmacist intervention.
Fourth, a follow-up period of 6 months may be too short to be
able to evaluate long term costs and effects of the intervention such
as relapse of depression. Higher rates of adherence have been
associated to a lower risk of relapse which could reduce the costs
[12].
An important strength is that this was a naturalistic study with
very wide inclusion criterion, which was conducted in two different
populations and where the intervention was implemented by many
different community pharmacists. This increases the generalisa-
bility of the results while this also could have introduced
heterogeneity. The proportion of men and women differed
between groups and only half of the sample met DSM-IV
criteria for major depression. However, with exception of the
unadjusted analysis, all the models were controlled for gender
and the presence of major depression was tested as an adjusting
variable in all the models and included when necessary. Also, a
sensitivity analysis of the patients that presented major
depression according to DSM-IV criteria has been included.
Moreover, patients could decide whether to refill their
prescription and move from one to another pharmacy in
successive visits. Consequently, 26% of the patients in the
intervention group did not receive the intervention as allocated.
However, we think that this is representative of daily clinical
practice and that this greatly improves the generalisability of the
results.
Finally, the main clinical outcome, adherence to antidepres-
sants, was measured using electronic pharmacy records. Patients
could have refilled prescription but not take them. However, this
method has two advantages: patients are unaware of the fact that
their adherence to medication is being observed and information
Table 4. Mean pooled differences in total effects and costs at 6 months follow-up and results of cost-effectiveness and cost-utility
analyses after 6 months follow-up for the main analysis and for the sensitivity analyses.
Sample size Outcome
Cost difference
J (95% CI BCa)
Effect difference
(95% CI) ICER/ICUR Distribution CE-plane
I C %NE %SE %SW %NW
Main analysis* 87 92 Adherence 74 (2163, 13510) 0.04 (20.2, 0.1) 1866 63.9 6.9 3.0 26.2
PHQ-9 74 (2163, 13510) 20.01 (20.2, 0.1) 27651 41.4 4.9 5.0 48.8
QALY 74 (2163, 13510) 0.01 (20.02, 0.03) 9872 68.1 7.8 2.1 22.0
Main analysis (unadjusted) 87 92 Adherence 312 (236, 677) 0.06 (20.1, 0.2) 5409 73.2 3.9 1.3 21.6
PHQ-9 312 (236, 677) 20.02 (20.2, 0.1) 218930 42.2 2.2 3.0 52.6
QALY 312 (236, 677) 20.005 (20.04, 0.03) 264181 35.1 2.2 3.0 59.7
Healthcare perspective* 87 92 Adherence 38 (258, 159) 0.04 (20.2, 0.1) 962 50.6 20.2 8.9 20.4
PHQ-9 38 (258, 159) 20.01 (20.2, 0.1) 23946 32.4 13.9 15.2 38.6
QALY 38 (258, 159) 0.01 (20.02, 0.03) 5092 53.6 22.3 6.8 17.4
Sensitivity analyses*
Per Protocol analysis 64 87 Adherence 163 (2126, 92275008) 0.11 (20.2, 0.2) 1455 86.1 3.4 0.5 10.0
PHQ-9 163 (2126, 92275008) 20.04 (20.2, 0.2) 24350 40.2 2.0 1.9 55.9
QALY 163 (2126, 92275008) 0.01 (20.02, 0.04) 25522 60.7 2.8 1.1 35.4
Complete cases 62 65 Adherence 11 (2258, 387) 0.02 (223.3, 0.2) 696 56.9 7.4 5.2 30.6
PHQ-9 11 (2258, 387) 0.03 (20.1, 0.2) 715 56.6 8.6 4.0 30.8
QALY 11 (2258, 387) 0.02 (20.01, 0.05) 601 81.4 11.5 1.0 6.0
Double intervention costs 87 92 Adherence 93 (2146, 683) 0.04 (20.2, 0.1) 2333 65.7 5.1 2.2 27.0
PHQ-9 93 (2146, 683) 20.01 (20.2, 0.1) 29569 43.0 3.2 4.0 49.7
QALY 93 (2146, 683) 0.01 (20.02, 0.03) 12347 70.7 5.1 2.1 22.0
Average salary for absenteeism 87 92 Adherence 159 (2299, 1.1*109) 0.04 (20.2, 0.1) 3997 66.9 5.6 2.3 25.1
PHQ-9 159 (2299, 1.1*109) 20.01 (20.2, 0.2) 216392 44.3 3.5 4.4 47.7
QALY 159 (2299, 1.1*109) 0.01 (20.02, 0.03) 21152 70.4 5.7 2.3 21.6
DSM-IV criteria for depression 45 45 Adherence 14 (21.4*107, 6.0*109) 0.02 (20.1, 0.2) 574 63.4 6.8 3.2 26.6
PHQ-9 14 (21.4*107, 6.0*109) 0.03 (20.1, 0.2) 469 42.9 5.3 4.7 47.1
QALY 14 (21.4*107, 6.0*109) 0.0004 (20.03, 0.03) 32895 67.1
*Models with costs as dependent variable adjusted for gender, costs in the previous three months and baseline severity of depression. Models with adherence as
dependent variable adjusted for gender and age. Models with reduction of symptoms (50% or over reduction in PHQ-9) as dependent variable adjusted for gender,
comorbidities and presence of major depression. Models with quality adjusted life years (QALY) as dependent variable adjusted for gender, age and baseline quality of life.
doi:10.1371/journal.pone.0070588.t004
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Figure 2. Cost-effectiveness plane for adherence with antidepressant therapy (pharmacist intervention vs usual care) and cost-
effectiveness acceptability curves for adherence with antidepressant therapy, remission of depressive symptoms (PHQ-9) and
QALYs estimated using bootstrapping from the societal perspective. The central white dot in the cost-effectiveness plane indicates the
point estimate of the incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0070588.g002
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can be collected even when patients drop-out from the study,
avoiding missing data for our primary outcome.
Conclusions
A brief CPI to improve adherence to antidepressants in patients
initiating pharmacological treatment for depression, after 6
months follow-up, showed a maximum probability of being cost-
effective of 0.71 and 0.75 in terms of improvement of adherence
and QALY, respectively, when compared to UC. In view of the
available evidence, we cannot recommend regular implementation
of low intensity pharmacist interventions addressed to improve
adherence to antidepressants in depressed patients.
The cost-effectiveness of more complex pharmacist’s interven-
tions needs to be evaluated before its implementation. In future
studies, a longer follow-up period and the use of cluster
randomization that limits contamination is recommended. Con-
sidering the uncertainty surrounding the costs in the sample size
calculations is also necessary.
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(PDF)
Acknowledgments
We are grateful to the patients, community pharmacists and general
practitioners from Gava` and El Prat the Llobregat for their participation in
the study.
Author Contributions
Conceived and designed the experiments: MRV ASB MPM MM PT .
Performed the experiments: MRV AF MPM MM PT. Analyzed the data:
MRV JB AF JAB . Wrote the paper: MRV JB AF MPM MM PT JAB ASB.
References
1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, et al. (2004)
Prevalence of mental disorders in Europe: results from the European Study of
the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand
Suppl: 21–27.
2. Mathers CD, Loncar D (2006) Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 3: e442. Available: http://www.
plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0030442
3. Sturm R, Wells KB (1995) How can care for depression become more cost-
effective? JAMA 273: 51–58.
4. Sobocki P, Jonsson B, Angst J, Rehnberg C (2006) Cost of depression in Europe.
J Ment Health Policy Econ 9: 87–98.
5. Commission of the European Communities (2005) Green Paper. Improving the
mental health of the population. Towards a strategy on mental health for the
European Union. Brussels.
6. Salvador-Carulla L, Bendeck M, Fernandez A, Alberti C, Sabes-Figuera R, et
al. (2011) Costs of depression in Catalonia (Spain). J Affect Disord 132: 130–
138.
7. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, et al. (2004) Use
of mental health services in Europe: results from the European Study of the
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand
Suppl: 47–54.
8. Rubio-Valera M, Fernandez A, Luciano JV, Hughes CM, Pinto-Meza A, et al.
(2012) Psychotropic prescribing in Catalonia: results from an epidemiological
study. Fam Pract 29: 154–162.
9. Chen SY, Hansen RA, Gaynes BN, Farley JF, Morrissey JP, et al. (2010)
Guideline-concordant antidepressant use among patients with major depressive
disorder. Gen Hosp Psychiatry 32: 360–367.
10. Prukkanone B, Vos T, Burgess P, Chaiyakunapruk N, Bertram M (2010)
Adherence to antidepressant therapy for major depressive patients in a
psychiatric hospital in Thailand. BMC Psychiatry 10: 64. Available: http://
www.biomedcentral.com/1471-244X/10/64
11. Serna MC, Cruz I, Real J, Gasco E, Galvan L (2010) Duration and adherence of
antidepressant treatment (2003 to 2007) based on prescription database. Eur
Psychiatry 25: 206–213.
12. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, et al. (2003)
Relapse prevention with antidepressant drug treatment in depressive disorders: a
systematic review. Lancet 361: 653–661.
13. Simon GE (2002) Evidence review: efficacy and effectiveness of antidepressant
treatment in primary care. Gen Hosp Psychiatry 24: 213–224.
14. Demyttenaere K, Adelin A, Patrick M, Walthe`re D, Katrien de B, et al. (2008)
Six-month compliance with antidepressant medication in the treatment of major
depressive disorder. Int Clin Psychopharmacol 23: 36–42.
15. Chong WW, Aslani P, Chen TF (2011) Effectiveness of interventions to improve
antidepressant medication adherence: a systematic review. Int J Clin Pract 65:
954–975.
16. Rubio-Valera M, Serrano-Blanco A, Magdalena-Belio J, Fernandez A, Garcia-
Campayo J, et al. (2011) Effectiveness of pharmacist care in the improvement of
adherence to antidepressants: a systematic review and meta-analysis. Ann
Pharmacother 45: 39–48.
17. Rubio-Valera M, March Pujol M, Ferna´ndez A, Pen˜arrubia-Marı´a MT, Trave´
P, et al. (2012) Evaluation of a pharmacist intervention on patients initiating
pharmacological treatment for depression: A randomized controlled superiority
trial. Eur Neuropsychopharmacol In press. Available: http://www.
europeanneuropsychopharmacology.com/article/S0924-977X(12)00318-5/
abstract
18. Bosmans JE, Brook OH, Van Hout HP, de Bruijne MC, Nieuwenhuyse H, et al.
(2007) Cost effectiveness of a pharmacy-based coaching programme to improve
adherence to antidepressants. Pharmacoeconomics 25: 25–37.
19. Glick HA, Doshi JA, Sonnad SS, Polsky D (2007) Economic evaluation in
clinical trials. Oxford University Press.
20. Rubio-Valera M, Serrano-Blanco A, Trave P, Penarrubia-Maria MT, Ruiz M,
et al. (2009) Community pharmacist intervention in depressed primary care
patients (PRODEFAR study): randomized controlled trial protocol. BMC Public
Health 9: 284. Available: http://www.biomedcentral.com/1471-2458/9/284
21. First MB, Spitzer RL, Gibbon M, William JB (1996) Structured Clinical
Interview Axis I DSM-IV Disorders, Research Version (SCID-RV). Washing-
ton: American Psychiatric Press, Inc.
22. First MB, Spitzer RL, Gibbon M, William JB (1999) Entrevista clı´nica
estructurada para los trastornos del eje I del DSM-IV. Barcelona, Spain:
Masson ed.
23. Hansen RA, Kim MM, Song L, Tu W, Wu J, et al. (2009) Comparison of
methods to assess medication adherence and classify nonadherence. Ann
Pharmacother 43: 413–422.
24. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, et al. (2007) A
checklist for medication compliance and persistence studies using retrospective
databases. Value Health 10: 3–12.
25. The EuroQol Group (1990) EuroQol–a new facility for the measurement of
health-related quality of life. Health Policy 16: 199–208.
26. Badia X, Schiaffino A, Alonso J, Herdman M (1998) Using the EuroQoI 5-D in
the Catalan general population: feasibility and construct validity. Qual Life Res
7: 311–322.
27. Badia X, Roset M, Montserrat S, Herdman M, Segura A (1999) [The Spanish
version of EuroQol: a description and its applications. European Quality of Life
scale]. Med Clin (Barc) 112: 79–85.
28. Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol:
Results from a UK general population survey. University of York: Centre for
Health Economics. Discussion Paper 138.
29. Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report
version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation
of Mental Disorders. Patient Health Questionnaire. JAMA 282: 1737–1744.
30. Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief
depression severity measure. J Gen Intern Med 16: 606–613.
31. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011) Exploratory analyses
of efficacy data from major depressive disorder trials submitted to the US Food
and Drug Administration in support of new drug applications. J Clin Psychiatry
72: 464–472.
32. Knapp M (PSSRU and Centre for Economics of Mental Health IoP, University
of Kent) (1995) The Economic evaluation of Mental Health Care. Ashgate
Publishing Group.
33. [Resolution SLT/383/2009 of 21 January 2009 of the Official Gazette of the
Catalan Government (Diari Oficial de la Generalitat de Catalunya) DOGC
Number 5325].
34. Official College of Medical Doctors of Barcelona. Available: http://www.comb.
cat/home.aspx. Accessed 2012 February 15.
35. Spanish National Institute of Statistics. Available: www.ine.es. Accessed 2012
March 5.
36. ASPIME (2011) XII Edition of the Annual Report on Community Pharmacies.
37. White IR, Royston P, Wood AM (2011) Multiple imputation using chained
equations: Issues and guidance for practice. Stat Med 30: 377–399.
38. Rubin D (1987) Multiple imputation for nonresponse in surveys. New York:
Wiley.
Pharmacist Care in Depression: Cost-Effectiveness
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e70588
39. Efron B (1994) Missing data, imputation, and the bootstrap. J Am Stat Assoc 89:
463–475.
40. Fenwick E, Byford S (2005) A guide to cost-effectiveness acceptability curves.
Br J Psychiatry 187: 106–108.
41. Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, et al.
(2001) Cost-effectiveness of practice-initiated quality improvement for
depression: results of a randomized controlled trial. JAMA 286: 1325–
1330.
Pharmacist Care in Depression: Cost-Effectiveness
PLOS ONE | www.plosone.org 10 August 2013 | Volume 8 | Issue 8 | e70588
